Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
about
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cutaneous head and neck melano ...... d stage IIIB/IIIC/IV melanoma.
@en
Cutaneous head and neck melano ...... d stage IIIB/IIIC/IV melanoma.
@nl
type
label
Cutaneous head and neck melano ...... d stage IIIB/IIIC/IV melanoma.
@en
Cutaneous head and neck melano ...... d stage IIIB/IIIC/IV melanoma.
@nl
prefLabel
Cutaneous head and neck melano ...... d stage IIIB/IIIC/IV melanoma.
@en
Cutaneous head and neck melano ...... d stage IIIB/IIIC/IV melanoma.
@nl
P2093
P2860
P356
P1433
P1476
Cutaneous head and neck melano ...... ed stage IIIB/IIIC/IV melanoma
@en
P2093
David W Ollila
Howard L Kaufman
John J Nemunaitis
Kevin J Harrington
Mark Shilkrut
Merrick Ross
Robert H I Andtbacka
Sanjiv S Agarwala
Sigrun Hallmeyer
P2860
P304
P356
10.1002/HED.24522
P50
P577
2016-07-13T00:00:00Z